Fractyl Health
GUTS | NASDAQ
$0.99
+$0.09 (+9.56%)
At close: Nov 16, 2026, 4:00 PM ET
$0.97
-$0.02 (-1.54%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Fractyl Health Company Profile
Company profile explainedCompany Profile
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
Key Executives
| Name | Position |
|---|---|
| Harith Rajagopalan | Co-Founder, CEO, Director & Principal Executive Officer |
| Lara Smith Weber | Chief Financial Officer & Treasurer |
| Brian Luque | Head of Investor Relations & Corporate Development |
| Jay D. Caplan BSEE | Co-Founder, Chief Product Officer & President |
| Jon Fitzgerald | Senior Vice President of Regulatory, Quality & Clinical |
| Mike Zumdahl | Senior Vice President of Market Access & Commercial Strategy |
| Sarah S. Toomey | General Counsel & Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 22, 2026 | 8-K | Current Report |
| Oct 16, 2026 | 8-K | Current Report |
| Oct 13, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Oct 01, 2026 | 8-K | Current Report |
| Sep 24, 2026 | 8-K | Current Report |
| Sep 16, 2026 | 4 | Filing |
| Sep 11, 2026 | 8-K | Current Report |
| Aug 24, 2026 | DEF 14A | Filing |
| Aug 14, 2026 | PRE 14A | Filing |
| Aug 10, 2026 | 10-Q | Quarterly Report |
Fractyl Health
| Country | United States |
| IPO Date | Feb 2, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 100 |
| CEO | Harith Rajagopalan |
Contact Details
3 Van de Graaff Drive Burlington,
Massachusetts 01803 United States
Stock Details
| Ticker Symbol | GUTS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001572616 |
| CUSIP Number | 35168W202 |
| ISIN Number | US35168W2026 |
| SIC Code | 3841 |
Add to Watchlist
Select watchlists to add or remove GUTS